Gliclazide modified release: From once-daily administration to 24-hour blood glucose control
Abstract
Although sulfonylureas have been used for more than 40 years, it is only recently that their molecular mechanisms of action have been elucidated. Gliclazide modified release, whose introduction comes soon after the sequencing and cloning of the sulfonylurea receptor, is the first sulfonylurea for which it is possible to detail its action from the moment of oral administration through to its effects on long-term glycemic control. Piecing together these steps for this new agent underlines the rationality of its development and the important differences from other members of the sulfonylurea class. Employing an innovative pharmaceutical form based on a hydrophilic matrix to deliver this short-acting sulfonylurea, gliclazide modified release is associated with an unsurpassed efficacy:acceptability ratio, with the potential additional advantages inherent in reduced dosage and once-daily administration.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The risk of hypoglycemia of each sulfonylurea relates to its pharmacokinetic properties and is highest with long-acting sulfonylureas such as chlorpropamide, glyburide (glibenclamide), and long-acting glipizide.
“The risk of hypoglycemia of each sulfonylurea relates to its pharmacokinetic properties (104 -108) and is highest with long-acting sulfonylureas such as chlorpropamide, glyburide (glibenclamide), and long-acting glipizide (101,109 -111).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [107]
Cites
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085 · see citing works
Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin Secretion
Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., & Nelson, D. A. (1995) · Science · doi:10.1126/science.7716547 · Cited by 1,315 · see citing works
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313 · see citing works
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272 · see citing works
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873 · see citing works
Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM
Reaven, G. M., Hollenbeck, C., Jeng, C.-Y., Wu, M. S., & Chen, Y.-D. I. (1988) · Diabetes · doi:10.2337/diab.37.8.1020 · Cited by 753 · see citing works
A desktop guide to Type 2 diabetes mellitus
European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670 · see citing works
ATP-sensitive K+ channels and insulin secretion: their role in health and disease
Ashcroft, F., & Gribble, F. (1999) · Diabetologia · doi:10.1007/s001250051247 · Cited by 435 · see citing works
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408 · see citing works
1998 clinical practice guidelines for the management of diabetes in Canada
Meltzer, S. J., Leiter, L. A., Daneman, D., Gerstein, H. C., Lau, D. C. W., Ludwig, S. M., Yale, J., Zinman, B., Lillie, D., & Steering, C. (1998) · Canadian Medical Association Journal · Cited by 378 · see citing works
Rates of hypoglycemia in users of sulfonylureas
Van Staa, T., Abenhaim, L., & Monette, J. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00024-3 · Cited by 211 · see citing works
Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents
Jennings, A. M., Wilson, R. M., & Ward, J. D. (1989) · Diabetes Care · doi:10.2337/diacare.12.3.203 · Cited by 194 · see citing works
Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM
Reaven, G. M., Hollenbeck, C., Jeng, C. Y., et al. (1988) · Diabetes · doi:10.2337/diabetes.37.8.1020 · Cited by 183 · see citing works
Bruttomesso, D., Pianta, A., Mari, A., Valerio, A., Marescotti, M. C., Avogaro, A., Tiengo, A., & Prato, S. D. (1999) · Diabetes · doi:10.2337/diabetes.48.1.99 · Cited by 166 · see citing works
Hosker, J. P., Rudenski, A. S., Burnett, M. A., Matthews, D. R., & Turner, R. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90064-4 · Cited by 125 · see citing works
Glibenclamide vs Gliclazide in Type 2 Diabetes of the Elderly
Tessier, D., Dawson, K., Tétrault, J. P., Bravo, G., & Meneilly, G. S. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00256.x · Cited by 116 · see citing works
Differential sensitivity of beta-cell and extrapancreatic K ATP channels to gliclazide
Gribble, F. M., & Ashcroft, F. M. (1999) · Diabetologia · doi:10.1007/s001250051236 · Cited by 107 · see citing works
Diminished Insulin Response to Hyperglycemia in Prediabetes and Diabetes
Colwell, J. A., & Lein, A. (1967) · Diabetes · doi:10.2337/diab.16.8.560 · Cited by 107 · see citing works
Tsiani, E., Ramlal, T., Leiter, L., Klip, A., & Fantus, I. G. (1995) · Endocrinology · doi:10.1210/endo.136.6.7750472 · Cited by 58 · see citing works
Hellman, B., Sehlin, J., & Täljedal, I. (1984) · European Journal of Endocrinology · doi:10.1530/acta.0.1050385 · Cited by 57 · see citing works
Kawaki, J., Nagashima, K., Tanaka, J., Miki, T., Miyazaki, M., Gonoi, T., Mitsuhashi, N., Nakajima, N., Iwanaga, T., Yano, H., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.10.2001 · Cited by 57 · see citing works
Gregorio, F., Ambrosi, F., Cristallini, S., Pedetti, M., Filipponi, P., & Santeusanio, F. (1992) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(92)90146-i · Cited by 47 · see citing works
Bak, J. F., Schmitz, O., Sorensen, N. S., & Pedersen, O. B. (1989) · Diabetes · doi:10.2337/diabetes.38.11.1343 · Cited by 47 · see citing works
Drouin, P. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00086-6 · Cited by 46 · see citing works
The metabolism of gliclazide in man
Oida, T., Yoshida, K., KAGEMOTO, A., Sekine, Y., & Higashijima, T. (1985) · Xenobiotica · doi:10.3109/00498258509045338 · Cited by 37 · see citing works
Harrower, A. D. B. (1985) · Current Medical Research and Opinion · doi:10.1185/03007998509109650 · Cited by 33 · see citing works
Self-citation4th Congress of the International Diabetes Federation
(1960) · Diabetes · doi:10.2337/diab.9.5.438c · Cited by 33 · see citing works
Is sulphonylurea therapy effective long term? A 3-year study with gliclazide
Hernández, J. Z., & Lavielle, R. (1986) · Current Medical Research and Opinion · doi:10.1185/03007998609111102 · Cited by 18 · see citing works
Cathelineau, G., Champvallins, M. D., Bouallouche, A., & Lesobre, B. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90314-0 · Cited by 17 · see citing works
CONGRESS OF THE INTERNATIONAL DIABETES FEDERATION
Rakoff, A. E. (1952) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-12-2-253a · Cited by 16 · see citing works
Guillausseau, P.-J. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90417-v · Cited by 11 · see citing works
No effect of gliclazide on gastric inhibitory polypeptide (GIP) in type II diabetes
Scott, R. S., & Donnelly, T. (1987) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(87)80024-4 · Cited by 4 · see citing works
UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435 · see citing works
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138 · see citing works
Barnett, A. H., Krentz, A. J., Strojek, K., Sieradzki, J., Azizi, F., Embong, M., Imamoglu, S., Perušičová, J., Uličiansky, V., & Winkler, G. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00894.x · Cited by 106 · see citing works
Schernthaner, G. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00215-4 · Cited by 66 · see citing works
McGavin, J. K., Perry, C. M., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262090-00010 · Cited by 61 · see citing works
Şahin, İ., Bakıner, O., Demir, T., Sari, R., & Atmaca, A. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01612-8 · Cited by 64 · see citing works
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43 · see citing works
Varshosaz, J., Tavakoli, N., Minayian, M., & Rahdari, N. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9191-8 · Cited by 42 · see citing works
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 40 · see citing works
Gliclazide modified release*: results of a 2‐year study in patients with type 2 diabetes
Drouin, P., Standl, E., & for the Diamicron MR Study Group (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00404.x · Cited by 39 · see citing works
Shao, H., Ren, X., Liu, N. F., Chen, G. M., Li, W. L., Zhai, Z.-H., & Wang, D. W. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01134.x · Cited by 30 · see citing works
Vynckier, A., Voorspoels, J., Remon, J. P., & Vervaet, C. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12521 · Cited by 15 · see citing works
Ling, G., Sun, J., Tang, J., Xu, X., Sun, Y. H., & Zhong-gui, H. (2006) · Analytical Letters · doi:10.1080/00032710600668541 · Cited by 15 · see citing works
Bezerra, K. D. C., Pinto, E. C., Cabral, L. M., & de Sousa, V. P. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00933 · Cited by 14 · see citing works
Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers
Rojanasthien, N., Autsavakitipong, T., Kumsorn, B., Manorot, M., & Teekachunhatean, S. (2012) · ISRN Pharmacology · doi:10.5402/2012/375134 · Cited by 13 · see citing works
Evaluating gliclazide for the treatment of type 2 diabetes mellitus
Tomlinson, B., Li, Y.-H., & Chan, P. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2141108 · Cited by 12 · see citing works
Overcoming the hurdles to achieving glycemic control
Shaw, K. M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.001 · Cited by 10 · see citing works
Hypoglycaemia in Type 2 Diabetes and in Elderly People
Zammitt, N. N., & Frier, B. M. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch12 · Cited by 8 · see citing works
Naidoo, P., Rambiritch, V., & Mayet, L. (2006) · Current Therapeutic Research · doi:10.1016/j.curtheres.2006.04.001 · Cited by 7 · see citing works
PHARMACOLOGICAL TREATMENT OF TYPE 2 DIABETES
Hermans, M. P., & Buysschaert, M. (2004) · Acta Clinica Belgica · doi:10.1179/acb.2004.008 · Cited by 7 · see citing works
Al‐Kassas, R., Madni, A., Buchanan, C. M., & Shelling, A. N. (2021) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-021-09536-7 · Cited by 6 · see citing works
Kumar, V., Mazumder, B., Sharma, P. P., & Ahmed, Y. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00494-9 · Cited by 6 · see citing works
Khalil, S. S., Ali, H. A., Al-Saadawy, H. A., & El-Dawy, K. (2018) · Slovenian Veterinary Research · doi:10.26873/svr-654-2018 · Cited by 5 · see citing works
Udayakumar, T. S., Suresh, A. G., & Ubaidulla, U. (2013) · Cited by 4 · see citing works
WANGNOO, S. K., Shunmugavelu, M., Reddy, S. V. B., Negalur, V. B., Godbole, S. V., Dhandhania, V. K., Krishna, N., & Gaurav, K. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100102 · Cited by 3 · see citing works
Optimisation of an in vitro model for anti-diabetic screening
Wilson, G. P. (2006) · Nelson Mandela University Research Repository · Cited by 3 · see citing works
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Metzendorf, M., Richter, B., & Hemmingsen, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368 · Cited by 2 · see citing works
Winkler, G. (2015) · Orvosi Hetilap · doi:10.1556/oh.2015.30114 · Cited by 1 · see citing works
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1 · see citing works
Krishna, M. V., & Rao, T. V. (2014) · Cited by 1 · see citing works
- Authors
- Harrower, A.
- Affiliations
- Monklands Hospital (GB)
- Corresponding author
- Harrower, Andrew
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2000-10
- Volume
- 49
- Issue
- 10
- Pages
- 7-11
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2087781713
- Cited by
- 30
- References
- 35
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 3 · 2019: 1 · 2018: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 1
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- gliclazide modified release, sulfonylureas, sulfonylurea receptor, long-term glycemic control, once-daily dosing, oral glucose-lowering agents, type 2 diabetes
- MeSH terms
- Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Gliclazide, Humans, Hypoglycemic Agents, Insulin, Receptors, Drug, Potassium Channels, ATP-Binding Cassette Transporters, Potassium Channels, Inwardly Rectifying, Sulfonylurea Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
